ANI Pharmaceuticals Inc (ANIP) - Total Liabilities
Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has total liabilities worth $899.65 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ANI Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
ANI Pharmaceuticals Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how ANI Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See ANI Pharmaceuticals Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
ANI Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Karooooo Ltd
JSE:KRO
|
South Africa | ZAC2.47 Billion |
|
Bausch Health Companies Inc
TO:BHC
|
Canada | CA$25.58 Billion |
|
Twenty One Capital, Inc.
NYSE:XXI
|
USA | $108.82 Million |
|
NP3 Fastigheter AB
ST:NP3
|
Sweden | Skr17.22 Billion |
|
Kansai Nerolac Paints Limited
NSE:KANSAINER
|
India | Rs18.86 Billion |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
China | CN¥3.55 Billion |
|
McGraw Hill, Inc.
NYSE:MH
|
USA | $4.87 Billion |
|
Five-Star Business Finance Limited
NSE:FIVESTAR
|
India | Rs86.28 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down ANI Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ANIP company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ANI Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual total liabilities of ANI Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $899.65 Million | +5.20% |
| 2024-12-31 | $855.17 Million | +91.39% |
| 2023-12-31 | $446.82 Million | +6.00% |
| 2022-12-31 | $421.55 Million | +2.10% |
| 2021-12-31 | $412.86 Million | +55.51% |
| 2020-12-31 | $265.49 Million | +8.81% |
| 2019-12-31 | $244.00 Million | +4.57% |
| 2018-12-31 | $233.34 Million | -1.70% |
| 2017-12-31 | $237.38 Million | +54.93% |
| 2016-12-31 | $153.22 Million | +22.39% |
| 2015-12-31 | $125.18 Million | +1.02% |
| 2014-12-31 | $123.92 Million | +3402.66% |
| 2013-12-31 | $3.54 Million | -66.60% |
| 2012-12-31 | $10.59 Million | -56.87% |
| 2011-12-31 | $24.56 Million | -4.12% |
| 2010-12-31 | $25.62 Million | +24.33% |
| 2009-12-31 | $20.61 Million | +434.82% |
| 2008-12-31 | $3.85 Million | +154.18% |
| 2007-12-31 | $1.52 Million | -64.74% |
| 2006-12-31 | $4.30 Million | +56.03% |
| 2005-12-31 | $2.76 Million | +44.52% |
| 2004-12-31 | $1.91 Million | +116.38% |
| 2003-12-31 | $881.21K | -29.85% |
| 2002-12-31 | $1.26 Million | +35.40% |
| 2001-12-31 | $927.76K | -1.43% |
| 2000-12-31 | $941.26K | +186.00% |
| 1999-12-31 | $329.12K | -59.76% |
| 1998-12-31 | $817.91K | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more